Tag: David Schwartz
Skadden, Latham & Watkins steer USD1.12bn biotech sale
Skadden and Latham & Watkins are advising Otsuka Pharmaceutical on its USD1.12 billion acquisition of Jnana Therapeutics
BJContinent achieves first reverse US takeover under new rules
Gibson Dunn, Orrick, and DeHeng facilitate BJContinent's historic reverse US takeover under new rule



















